I now have comprehensive content from multiple authoritative sources. Let me compile the full answer.
Peyronie's Disease (PD)
Definition
Peyronie's disease is an acquired, progressive connective-tissue disorder of the tunica albuginea of the penis. Also called plastic induration of the penis, it leads to penile pain, penile curvature or deformity, palpable fibrous plaques, and - in many cases - difficulty or inability to have penetrative intercourse. It significantly affects quality of life and psychological well-being in both patients and their partners.
- Smith and Tanagho's General Urology, 19th Ed., p. 557
- Bailey and Love's Short Practice of Surgery, 28th Ed., p. 1572
Epidemiology
- Prevalence estimated at 3-9% of the male population; true prevalence may be higher.
- Most common between ages 45-60, but 10% of patients are younger than 40 (including teenagers).
- More common in Caucasian men.
- Associated conditions:
- Type 2 diabetes mellitus: 8% of diabetics develop PD
- Radical prostatectomy: 16% incidence of post-op PD
- Dupuytren's contracture: up to 21% of those with DC also have PD (shared gene expression patterns for collagen degradation, ossification, and myofibroblast differentiation)
- Erectile dysfunction (ED): present in 20-50% of men with PD
- Anxiety, depression, and relationship disorders affect >50% of PD patients; notably, distress does not always correlate with degree of curvature.
Pathogenesis
The exact cause is unknown, but the leading hypothesis involves:
- Repetitive microtrauma to the erect penis during intercourse (or occasionally trauma to the flaccid penis)
- Microhemorrhage between layers of the tunica albuginea (delamination)
- Initiation of the wound-healing cascade with aberrant fibrous tissue deposition
- Formation of relatively inelastic fibrous plaques beneath the tunica
Additional contributing factors include: genetic predisposition, autoimmune mechanisms, and localized wound-healing aberrations. Trauma alone cannot explain the disease - in one study of 193 penile fracture patients, none developed PD - so a susceptibility cofactor is required.
Dorsal and ventral shear stresses during intercourse likely explain why plaques are more often found dorsally, causing the characteristic dorsal curvature (toward the abdomen).
- Campbell Walsh Wein Urology, 3-Volume Set, p. 2134
Natural History - Two Phases
| Phase | Timing | Features |
|---|
| Acute (Active/Inflammatory) | Onset to ~6-12 months | Penile pain (35-45% of patients), plaque growth, progressive deformity; pain typically resolves within 6 months in 90% |
| Chronic (Fibrotic/Stable) | After 6-12 months | Plaque and curvature stabilize; spontaneous improvement is rare |
Without treatment: curvature worsens in 30-50%, stabilizes in ~47%, and spontaneously improves in a minority. The disease typically progresses for 18-24 months before stabilizing.
- Bailey and Love's Short Practice of Surgery, 28th Ed., p. 1572
- Smith and Tanagho's General Urology, 19th Ed., p. 578
Clinical Features
- Penile deformity - most commonly dorsal curvature (toward the abdomen)
- Palpable fibrous plaque(s) in the tunica albuginea
- Pain on erection (especially in the acute phase)
- Erectile dysfunction - multifactorial (pain, functional disability from curvature, vascular disease causing flail penis, psychogenic)
- Rarely: calcified plaques (visible on imaging)
Diagnosis
- Primarily clinical - history and physical examination (palpable plaque)
- Patient-produced photography of a natural erection or erection obtained by vacuum device/intracavernosal vasoactive injection for objective curvature assessment
- Ultrasonography - highest sensitivity for plaque detection (both calcified and soft-tissue elements); Doppler duplex US also assesses penile vascular status
- MRI - useful in select cases (shows active vs. calcified plaque)
MRI in Peyronie's disease: yellow arrow = calcified plaque; red arrow = active disease on the dorsal wall of the penis. (Bailey and Love, 28th Ed.)
Treatment
General Principles
- Treatment selection depends on: stage of disease, presence of pain, severity/direction of curvature, penile length, and erectile status.
- Surgery is not indicated during the active phase; conservative/medical measures are used first.
- Surgical correction is reserved for the stable (chronic) phase when deformity prevents intercourse.
1. Nonsurgical / Medical Treatment (Active Phase)
Oral Therapy
- Pentoxifylline (first-line oral agent) - a nonspecific PDE inhibitor that inhibits TGF-beta 1-mediated inflammation, prevents type I collagen deposition, and increases nitric oxide. Used as part of multimodal therapy.
- Other agents tried (with mostly disappointing RCT evidence): colchicine, PDE5 inhibitors, vitamin E, potaba, tamoxifen, carnitine, coenzyme Q10, omega-3 fatty acids.
Intralesional Injection Therapy (three agents with RCT evidence)
| Agent | Mechanism | Outcomes | Adverse Effects |
|---|
| Collagenase clostridium histolyticum (CCH/Xiaflex) | Selectively degrades collagen types I and III; increases apoptosis of fibroblasts | 34% reduction in curvature (mean 17°) vs. 18% placebo; improved symptom bother | Contusions, ecchymosis, corporeal rupture (rare but serious) |
| Verapamil | Calcium-channel blocker; inhibits fibroblast proliferation, reduces ECM synthesis, increases collagenase activity | Reduces curvature and plaque-associated penile narrowing; improves quality of erection | Nausea, lightheadedness, penile pain, ecchymosis |
| Interferon alfa-2b | Decreases fibroblast proliferation; reduces collagen production; increases collagenase | 27% curvature decrease (13.5°) vs. 9% placebo | Flu-like symptoms, minor penile swelling/ecchymosis |
Collagenase CCH (Xiaflex) is the ONLY FDA-approved intralesional treatment for PD. It is restricted under a REMS program. Each treatment cycle = 2 injections 1-3 days apart; penile modeling begins 48 hours after the second injection. Minimum 6 weeks between cycles.
External Therapies
| Therapy | Notable Outcomes |
|---|
| Penile traction | Length increase 0.5-2.0 cm; curvature decrease ~20°; 85% overall satisfaction |
| Extracorporeal shockwave therapy (ESWT) | Improves pain and QoL; no curvature reduction |
| Electromotive drug administration (iontophoresis) | Verapamil + dexamethasone: curvature reduction 43° to 21°; verapamil alone: no benefit |
(Iontophoresis, topical therapies, ESWT, and radiation therapy are generally not recommended per evidence-based guidelines.)
2. Surgical Treatment (Stable Phase Only)
Indications: stable disease + deformity interfering with sexual intercourse (adequate erectile function required).
Option A - Plication (for adequate penile length)
- Nesbit technique or 16-dot technique
- The tunica albuginea is plicated on the side opposite to the maximum curvature
- Straightens the penis but slightly shortens it
Option B - Plaque Incision/Excision + Grafting
- Incision of the plaque + patch graft (e.g., bovine pericardial patch)
- Preferred when the penis is shorter or curvature is severe
- Corrects deformity without further shortening
Option C - Penile Prosthesis
- For patients with PD + significant ED
- Inflatable penile prosthesis + penile modeling over the device
Summary (Key Points)
- PD is a two-phase disease (active then stable)
- No effective treatment exists for the active phase - surgery is contraindicated until stabilization
- CCH (Xiaflex) is the only FDA-approved intralesional treatment
- Surgery (plication or graft) is offered in the stable phase for deformity that prevents intercourse
- Strong association with Dupuytren's contracture (fibromatosis)
- ED and psychological morbidity are common and should be actively addressed
Sources:
- Smith and Tanagho's General Urology, 19th Ed., pp. 557-605
- Bailey and Love's Short Practice of Surgery, 28th Ed., pp. 1572
- Campbell Walsh Wein Urology, 3-Volume Set, pp. 2134-2146
- Andrews' Diseases of the Skin, Clinical Dermatology
Recent evidence note: A 2025 systematic review (PMID
39186947) examined iontophoresis specifically for PD and found limited supportive data, consistent with current guidelines not recommending it. No major meta-analyses from 2024-2026 contradict the above management framework.